Previously, we demonstrated that linear peptide epoxyketones targeting the immunoproteasome (iP) could ameliorate cognitive deficits in mouse models of Alzheimer's disease (AD) independently of amyloid deposition. We also reported the first iP-targeting macrocyclic peptide epoxyketones, which exhibit improved metabolic stability compared with their linear counterparts. Here, we prepared additional macrocyclic peptide epoxyketones and compared them with existing macrocyclic iP inhibitors by assessing Caco2 cell-based permeability and microsomal stability, providing the four best macrocyclic iP inhibitors. We then evaluated the four compounds using the Ames test and the potency assays in BV2 cells, selecting compound as our AD drug lead. When was administered intravenously (40 mg/kg) or orally (150 mg/kg) into healthy BALB/c mice, we observed considerable iP inhibition in the mouse brain, indicating good blood-brain barrier permeability and target engagement. Combined results suggest that is a promising AD drug lead that may need further investigation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733980 | PMC |
| http://dx.doi.org/10.1021/acs.jmedchem.3c02488 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of novel epoxyketone macrocyclic peptidyl proteasome inhibitors through OPA-mediated one-step cyclization of unprotected peptides.
Bioorg Chem
January 2025
Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province School of Medicine Hangzhou City University China; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058 Zhejiang Province, China. Electronic address:
Cyclization is a pivotal strategy for enhancing the drug-like characteristics of polypeptides. To develop potent and metabolically stable proteasome inhibitors, we generated a macrocyclic peptide skeleton using a straightforward and efficient cyclization strategy. Subsequent stability assessments confirmed the practicality of this approach.
View Article and Find Full Text PDFDistinct substrate specificities of the three catalytic subunits of the Trichomonas vaginalis proteasome.
Protein Sci
December 2024
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Article Synopsis
- Trichomonas vaginalis (Tv) is a protozoan parasite that causes trichomoniasis, the most prevalent non-viral sexually transmitted infection globally, but current treatment options are limited and facing resistance issues.
- Researchers are targeting the proteasome, a key enzyme complex in eukaryotes, to develop new treatments by isolating the enzyme and identifying specific inhibitors for its three catalytic subunits (β1, β2, β5).
- By creating specialized substrates for each subunit and screening a library of inhibitors, the study found that targeting the Tv β5 subunit is particularly effective in killing the parasite, which may lead to improved drug development strategies against trichomoniasis.
Green RP-HPLC method for the estimation of carfilzomib in bulk, protein nanocarriers and human plasma: Application of chemometrics and Monte-Carlo simulations.
J Chromatogr B Analyt Technol Biomed Life Sci
December 2024
Emeritus Professor, Panjab University, Chandigarh, India.
Carfilzomib is a tetrapeptide epoxyketone that has shown potential clinical outcomes in the treatment of multiple myeloma. However, inaccuracies in quantifying such peptide drug products have arisen due to poor stability, low solubility, time-consuming techniques, complex physicochemical properties, and use of non-green solvents with less recyclability. This provides a substantial urge to develop an ecological and sensitive analytical method for quantifying peptide drugs from matrix formulation and biological samples in early as well as lateral stages of product development in pharma industries.
View Article and Find Full Text PDFEvaluating Antimalarial Proteasome Inhibitors for Efficacy in Blood Stage Cultures.
ACS Omega
November 2024
Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice 370 05, Czech Republic.
Tick-transmitted are a major global veterinary threat and an emerging risk to humans. Unlike their relatives, these erythrocyte-infecting Apicomplexa have been largely overlooked and lack specific treatment. Selective targeting of the proteasome holds promise for drug development.
View Article and Find Full Text PDFHeterologous Expression of Epoxomicin in .
ACS Synth Biol
September 2024
School of Biological Sciences, Victoria University of Wellington, Wellington 6012, New Zealand.
Epoxomicin is an epoxyketone proteasome inhibitor with synthetic derivatives approved or under investigation for treatment of multiple myeloma. To leverage the advantages of as a rapidly growing and readily engineered host for the production of epoxomicin and analogues, we expressed codon-optimized versions of the epoxomicin biosynthetic genes, , and . Epoxomicin was detected, but the major product was a ketone resulting from α,β-keto acid precursor decarboxylation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!